Phase II trial of taxol, an active drug in the treatment of metastatic breast cancer
- PMID: 1683908
- DOI: 10.1093/jnci/83.24.1797-a
Phase II trial of taxol, an active drug in the treatment of metastatic breast cancer
Abstract
Taxol, an antimicrotubule agent, has shown promise for efficacy in treatment of breast cancer, but severe hypersensitivity reactions led to cessation of many phase I clinical trials. Consequently, investigators and the National Cancer Institute recommended that phase I and II studies of this agent use 24-hour infusions and antiallergic medications. Using a premedication regimen effective in preventing hypersensitivity reactions, we have performed a phase II trial of taxol in patients with metastatic breast cancer. Taxol was administered to 25 patients at a dose of 250 mg/m2 by 24-hour infusion every 21 days. These patients had received only one prior chemotherapy regimen, either adjuvant to surgery or for metastatic disease; all but two had received doxorubicin. In 60% of the patients, the dominant site of disease was the viscera. All patients were assessable. In April 1991, at a median time on study of 9 months (range, 5-13+ months), the objective response rate was 56% (12% complete and 44% partial; 95% confidence interval, 35%-76%). Disease progressed in only 8% of the patients. The median number of courses of therapy was 11. Granulocytopenia was the dose-limiting toxic effect, but neutropenia with fever occurred in only 5% of 232 courses. A chronic glove-and-stocking neuropathy developed in most patients, but no allergic reactions occurred. We conclude that taxol is an active agent in the treatment of metastatic breast cancer and that it warrants continued study. Currently, we are conducting a phase I trial of taxol plus doxorubicin. Future trials should address the optimal effective dose, the optimal sequencing of combinations, mechanisms of drug resistance in tumors, and dose-limiting toxic effects (particularly cardiac toxic effects of taxol given as a single agent or in drug combinations).
Similar articles
-
A phase I/II study of sequential doxorubicin and paclitaxel in the treatment of advanced breast cancer.Semin Oncol. 1996 Oct;23(5 Suppl 11):16-22. Semin Oncol. 1996. PMID: 8893894 Clinical Trial.
-
Paclitaxel by 24-hour infusion with doxorubicin by 48-hour infusion as initial therapy for metastatic breast cancer: phase I results.Ann Oncol. 1999 Apr;10(4):403-11. doi: 10.1023/a:1008360406322. Ann Oncol. 1999. PMID: 10370782 Clinical Trial.
-
Paclitaxel in metastatic breast cancer: a trial of two doses by a 3-hour infusion in patients with disease recurrence after prior therapy with anthracyclines.J Natl Cancer Inst. 1995 Aug 2;87(15):1169-75. doi: 10.1093/jnci/87.15.1169. J Natl Cancer Inst. 1995. PMID: 7674322 Clinical Trial.
-
Treatment of metastatic breast cancer with paclitaxel and doxorubicin.Semin Oncol. 1995 Dec;22(6 Suppl 15):13-7. Semin Oncol. 1995. PMID: 8643964 Review.
-
Paclitaxel as first-line treatment for metastatic breast cancer. The Taxol Investigational Trials Group, Australia and New Zealand.Oncology (Williston Park). 1997 Apr;11(4 Suppl 3):19-23. Oncology (Williston Park). 1997. PMID: 9144686 Review.
Cited by
-
Dose-escalation phase I study in metastatic breast cancer patients with combination of paclitaxel and tegafur·uracil.Oncol Lett. 2010 Jan;1(1):45-49. doi: 10.3892/ol_00000008. Epub 2010 Jan 1. Oncol Lett. 2010. PMID: 22966254 Free PMC article.
-
Prediction of paclitaxel sensitivity by CDK1 and CDK2 activity in human breast cancer cells.Breast Cancer Res. 2009;11(1):R12. doi: 10.1186/bcr2231. Epub 2009 Feb 24. Breast Cancer Res. 2009. PMID: 19239702 Free PMC article.
-
Apoptosis Reversal Promotes Cancer Stem Cell-Like Cell Formation.Neoplasia. 2018 Mar;20(3):295-303. doi: 10.1016/j.neo.2018.01.005. Epub 2018 Feb 22. Neoplasia. 2018. PMID: 29476980 Free PMC article.
-
Phase II trial of taxol in patients with adenocarcinoma of the upper gastrointestinal tract (UGIT). The Eastern Cooperative Oncology group (ECOG) results.Invest New Drugs. 1995;13(3):223-7. doi: 10.1007/BF00873804. Invest New Drugs. 1995. PMID: 8729950 Clinical Trial.
-
The cytotoxic activity of Taxol in primary cultures of tumour cells from patients is partly mediated by Cremophor EL.Br J Cancer. 1995 Mar;71(3):478-81. doi: 10.1038/bjc.1995.97. Br J Cancer. 1995. PMID: 7880727 Free PMC article.
Publication types
MeSH terms
Substances
Grants and funding
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical
Miscellaneous